Format

Send to

Choose Destination
J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):378-398. doi: 10.1016/j.jvsv.2017.02.001.

Report of the Society for Vascular Surgery and the American Venous Forum on the July 20, 2016 meeting of the Medicare Evidence Development and Coverage Advisory Committee panel on lower extremity chronic venous disease.

Author information

1
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn. Electronic address: gloviczki.peter@mayo.edu.
2
Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis, Ind.
3
Section of Vascular Surgery, University of Michigan, Ann Arbor, Mich.
4
Department of Vascular Surgery, University of Maryland, Baltimore, Md.
5
Cardiovascular Center, Tufts Medical Center, Boston, Mass.
6
Division of Vascular Surgery, Department of Surgery, Duke University Medical Center, Durham, NC.
7
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.

Abstract

On July 20, 2016, a Medicare Evidence Development and Coverage Advisory Committee panel assessed the benefits and risks of currently used lower extremity chronic venous disease (CVD) treatments and their effects on health outcome of the American adult population. The main purpose of the meeting was to advise the Centers for Medicare & Medicaid Services on coverage determination for interventions used for treatment of CVD. A systematic review of the Agency for Healthcare Research and Quality was presented, followed by lectures of invited experts and a public hearing of representatives of professional societies and the industry. After discussing critical issues, the panel voted for key questions. This report summarizes the presented evidence to support recommendations of the Society for Vascular Surgery/American Venous Forum coalition and the presentations on selected discussion topics. These included important venous disease evidence gaps that have not been sufficiently addressed, venous disease treatment disparities and how they may affect the health outcomes of Medicare beneficiaries, and mechanisms that might be supported by the Centers for Medicare & Medicaid Services to improve the evidence base to optimize the care of patients with lower extremity CVD.

PMID:
28411706
DOI:
10.1016/j.jvsv.2017.02.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center